TICKERNERD
Menu
TNYATNYAHealthcare · Biotechnology

TNYA Stock Forecast: Tenaya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$0.73
−0.67% on the day

The 7 Wall Street analysts covering Tenaya Therapeutics, Inc. hold a median 12-month price target of $3 — +312.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$164.4M
Ticker Nerd rank
40 / 100
Median analyst target
$3.00
Analysts covering
7
Total return, dividends reinvested
1W
+0.2%
1M
−15.8%
YTD
+2.3%
1Y
−23.1%
From 52W high
−65.3%
From 52W low
+32.4%
$0.55
$2.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNYA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tenaya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Size
71
Issuance
61
Growth
54
Momentum
47
Quality
33
Revisions
27
Value
25
Volatility
20

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26TNYAHigh $5.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $2.00Median $3.00High $5.00

The green dot is the last close — the median target sits +312.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Chardan CapitalMaintainsBuy$8.00
12 Mar 2026Chardan CapitalMaintainsBuy—
18 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025Chardan CapitalMaintainsBuy—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
10 Nov 2025Chardan CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025Chardan CapitalMaintainsBuy—
9 May 2025Chardan CapitalMaintainsBuy—
25 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Canaccord GenuityMaintainsBuy—
12 Mar 2025Chardan CapitalMaintainsBuy—
12 Mar 2025Morgan StanleyMaintainsOverweight—
11 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024Chardan CapitalMaintainsBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNYA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TNYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Tenaya Therapeutics, Inc. (TNYA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
123.5×

Cheaper than 4% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
393.3%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1882.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−121.9%

Higher than 11% of US stocks

Return on assets
−47.9%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TNYA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNYATenaya Therapeutics, Inc.$164.4M
40
CNTNCanton Strategic Holdings, Inc.$155.8M
13
CNTBConnect Biopharma Holdings Ltd.$160.6M
20
OKUROnKure Therapeutics, Inc.$161.1M
55
HUMAHumacyte, Inc.$163.1M
18
SPRBSpruce Biosciences, Inc.$151.3M
31
HURATuHURA Biosciences, Inc.$150.0M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenaya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNYA news & analysis

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Seeking Alpha · 14 Aug 2026neutral

Tenaya Therapeutics presented at Canaccord Genuity's 46th Annual Growth Conference, as covered by Seeking Alpha with a transcript of the presentation. The item reports that the company participated in this investor conference.

Why it matters — A TNYA watcher would care because the company's remarks at a major growth conference can offer insight into its business and strategy.

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 5 Aug 2026positive

Tenaya Therapeutics reported its second quarter 2026 financial results and provided a corporate update, noting positive interim data from its MyPEAK-1 and RIDGE-1 clinical trials. The company also received a $10 million upfront payment from its Alnylam collaboration, extending its cash runway through Q3 2027, with additional data releases and regulatory discussions anticipated in Q4 2026.

Why it matters — TNYA watchers would care because the positive interim trial data, Alnylam collaboration payment, and extended cash runway indicate clinical progress and strengthened financial stability for the company.

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 4 Aug 2026neutral

Tenaya Therapeutics announced that members of its management will host 1x1 meetings with investors at the Canaccord Genuity 46th Annual Growth Conference, held August 11-12, 2026 in Boston, Massachusetts.

Why it matters — The meetings give investors an opportunity to hear directly from Tenaya management about the company at a major industry conference.

FAQ

Frequently asked questions about TNYA stock

What is the TNYA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Tenaya Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNYA stock a buy right now?

Of the 7 analysts covering Tenaya Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenaya Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNYA?

As at 15 Aug 2026, Tenaya Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will TNYA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +312.0% from the last close, and Ticker Nerd's factor model ranks Tenaya Therapeutics, Inc. 40 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNYA stock forecast for 2030?

No analyst covering Tenaya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has TNYA stock performed over the past year?

Tenaya Therapeutics, Inc. returned -23.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenaya Therapeutics, Inc. do?

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering gene therapy solutions for cardiovascular diseases.

What is the latest news on TNYA?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript". Tenaya Therapeutics presented at Canaccord Genuity's 46th Annual Growth Conference, as covered by Seeking Alpha with a transcript of the presentation. The item reports that the company participated in this investor conference.

Company

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering gene therapy solutions for cardiovascular diseases. Headquartered in South San Francisco, California, the company leverages a proprietary adeno-associated virus (AAV) platform to create potentially curative treatments for genetic heart conditions. Its lead program, TN-201, is a gene therapy currently in phase 2 clinical trials targeting myosin binding protein C3-associated hypertrophic cardiomyopathy. Additional pipeline candidates include TN-401, a gene therapy in phase 1 trials for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule therapeutic for heart failure with preserved ejection fraction. The company also develops gene therapy approaches for dilated cardiomyopathy and heart failure stemming from prior myocardial infarction. Tenaya operates primarily in the United States and collaborates with research partners to accelerate development timelines and expand scientific capabilities. The company's management team combines expertise in gene therapy, cardiovascular biology, and biopharmaceutical development to address unmet medical needs in inherited heart diseases.

CEO Mr. Faraz Ali M.B.A. · 70 employees · United States · https://www.tenayatherapeutics.com